ArticleClinical drug investigation2012
Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.
Article in Clinical drug investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 12 citations in OpenAlex.
- Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy.Journal of thrombosis and thrombolysis · 2020Article
- Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review.Pediatrics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWarfarin is a commonly used oral anticoagulant and its interaction with other drugs can result in serious thrombotic or bleeding events. Currently, there is no definitive evidence on the possibility of an interaction between warfarin and oseltamivir.
objectiveThe objective of this study was to investigate whether a possible drug interaction between oseltamivir and warfarin exists.
methodsA retrospective review of patients on anticoagulation therapy who took oseltamivir from 1 September 2009 to 28 February 2010 at Seoul National University Hospital, Seoul, Korea, was carried out.
resultsAmong 15 patients who were tested for prothrombin time/international normalized ratio (PT/INR) [hereafter referred to as INR] within 10 days of starting oseltamivir therapy and had previously stable INR values, seven patients had an increase in INR levels after oseltamivir administration, and the other eight patients maintained stable INR levels. The mean ± SD INR value was 2.08 ± 0.46 prior to the administration of oseltamivir and 5.15 ± 2.00 after treatment with oseltamivir (measured a mean ± SD 5.7 ± 2.5 days after the first dose of oseltamivir) in the INR-increased group and, respectively, 2.03 ± 0.40 and 1.97 ± 0.54 (measured 6.4 ± 2.5 days after the first dose of oseltamivir) in the INR-unaffected group. The dosage and duration of oseltamivir treatment were similar whether the INR values increased or not. There were bleeding events such as blood-tinged sputum and bloody ascites in three patients in the INR-increased group. The INR level recovered within 5 days after discontinuation of warfarin in these three patients. The positivity rates for influenza A H1N1 were not different between the INR-increased group and the INR-unaffected group.
conclusionThis case series suggests the possibility of a potential interaction between warfarin and oseltamivir. Further well designed prospective studies and genetic evaluations are needed to determine the exact nature of the interaction between warfarin and oseltamivir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.